AstraZeneca raises $750m amid US cholesterol drug fight

AstraZeneca, Europe's second-largest drugs group, has raised $750m (€629m) in the bond markets with the first deal since it was formed six years ago through an Anglo-Swedish merger. Citigroup, Goldman Sachs and JP Morgan ran the 10-year bond issue.

AstraZeneca, which has been in conflict with US consumer groups over the possible side-effects of Crestor, its cholesterol-lowering drug, declined to be drawn on the specific reasons for raising the new capital.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump